Expanding Role of SGLT 2 Inhibitors and Finererone in primary care. Dr Jeremy Knott

Expanding Role of SGLT 2 Inhibitors and Finererone Dr Jeremy Knott

In this podcast, Dr. Jeremy Knott explores the evolving landscape of diabetes management, specifically focusing on SGLT2 inhibitors and finerenone's role in addressing cardiorenal metabolic risks in type 2 diabetes. He emphasizes the need for a shift towards a comprehensive risk management strategy rather than a solely glycemic focus. The prevalence of type 2 diabetes in Australia is discussed, along with its significant associated cardiovascular risks. Dr. Knott outlines the pathophysiological mechanisms linking diabetes to cardiovascular and renal complications and presents evidence supporting the effectiveness of SGLT2 inhibitors and finerenone. He concludes with a call for early intervention and a holistic treatment approach that includes lifestyle modifications and adherence to updated clinical guidelines.

Enjoyed Today's Clinical Sessions Podcast?Imagine if your favourite medical conferences were available the same way.You already know how powerful learning by podcast can be.

No travel.

No sitting in lecture theatres.

No giving up another weekend.

Just practical education from leading clinicians, ready whenever you have time to listen.

That's exactly what ArmchairMedical.tv gives you.

Unlock hundreds of Australia's leading GP conferences and listen while you're driving to work, exercising, walking the dog or relaxing at home. When you want the full experience, simply switch to video and follow along with synchronised presentation slides.

Stay clinically up to date without putting your life on hold.

Spend less time travelling to conferences.

Spend more time with your friends and family and less time in auditoriums.